Overview
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Indication
Indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Associated Conditions
- Onychomycosis
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2017/09/13 | Phase 4 | Completed | |||
2017/05/30 | Phase 3 | Completed | |||
2017/04/12 | Phase 4 | Completed | |||
2017/04/04 | Phase 4 | Completed | |||
2017/01/18 | Not Applicable | Completed | |||
2016/06/24 | Phase 4 | Completed | |||
2009/11/05 | Phase 3 | Completed | Dow Pharmaceutical Sciences | ||
2009/11/04 | Phase 3 | Completed | Dow Pharmaceutical Sciences |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Bausch Health US LLC | 0187-5400 | TOPICAL | 100 mg in 1 mL | 3/31/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.